期刊文献+

完全生物可降解支架置入术及术后18个月随访一例 被引量:2

下载PDF
导出
摘要 2012年12月1日厦门市心脏中心为1例不稳定型心绞痛患者实施了完全生物可降解支架置入术,现将患者的基本情况、手术过程和术后18个月的随访情况报道如下。
机构地区 厦门市心脏中心
出处 《中国介入心脏病学杂志》 2014年第10期673-674,共2页 Chinese Journal of Interventional Cardiology
  • 相关文献

参考文献9

  • 1Nishio S, Kosuga K, Igaki K, et al. Long-Term(>10 Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents:Igaki-Tamai stents. Circulation, 2012, 125:2343-2353.
  • 2Onuma , Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation, 2011, 123:779-797.
  • 3Onuma , Serruys PW, Perkins LE, et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation, 2010, 122:2288-2300.
  • 4Onuma Y, Dudek D, Thuesen L, et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus- eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc lnterv, 2013, 6:999-1009.
  • 5Abizaid A, Costa JR Jr, Bartorelli AL, et al. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. Eurolntervention, 2014, [Epub ahead of print].
  • 6Rzeszutko L, Depukat R, Dudek D. Biodegradable vascular scaffold ABSORB BVS Tra _ scientific evidence and methods of implantation. Postepy Kardioi Inter, 2013, 9:22-30.
  • 7Serruys PW, Onuma Y, Garcia-Garcia HM, et al. Dynamics of vessel wall changes following the implantation of the absorb everolimus- eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. Eurolntervention, 2014, 9:1271-1284.
  • 8Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de- novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet, 2008, 37l:899-907.
  • 9Dudek D, Onuma Y, Ormiston JA, et al. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. Eurolntervention, 2012, 7:1060-1061.

同被引文献25

  • 1毕胜,纪树荣,顾越,瓮长水.Fugl-Meyer上肢运动功能评分与上肢运动功能状态评分的响应性研究[J].中国康复医学杂志,2006,21(2):118-120. 被引量:134
  • 2高润霖.药物洗脱支架研究现状及进展[J].中国实用内科杂志,2006,26(8):1121-1123. 被引量:19
  • 3脑卒中患者临床神经功能缺损程度评分标准(1995)[J].中华神经科杂志,1996,29(6):381-383. 被引量:15752
  • 4陈佳慧,沈雳,王齐兵,等.冠状动脉生物可降解支架设计与应用:材料学的进一步革新将带来什么?[J].中国组织工程研究,2014,18(30):4878-4888.
  • 5Jaruszewski KM,Curran GL,Swaminathan SK,et al. Multimodal Nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain.Biomaterials. 2014;35(6): 1967-1976.
  • 6Cheng T J, Ke DS, Guo HR,et aI.The association between arsenic exposure from drinking water and cerebrovascular disease mortality in Taiwan.Water Res. 2010;44(19): 5770-5776.
  • 7Inzitari D,Eliasziw M,Gates P, et aI.The causes and risk of stroke in patients with asympt0matic internal-carotid-artery stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators.N Engl J Med.2000; 342(23):1693-700.
  • 8Kono K,Shintani A,Tanaka Y, et aI.Delayed in-stent occlusion due to stent-related changes in vascular geometry after cerebral aneurysm treatment.Neurol Med Chit (Tokyo).2013 53(3):182-185.
  • 9Hunter TB,Yoshino MT, Dzioba RB,et aI.Medical devices of the head, neck, and spine.Radiographics.2004;24(1):257-285.
  • 10Fuchs C,Ladwig E,Zhou J,et al.Argatroban administration reduces leukocyte adhesion and improves capillary perfusion within the intestinal microcirculation in experimental sepsis. Thromb Haemost.2010; 104(5): 1022-1028.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部